Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is carcinoid tumors (well-differentiated neuroendocrine tumors)?
Carcinoid tumors are a type of well-differentiated neuroendocrine tumor — growths that begin in the body's neuroendocrine cells, specialized cells scattered throughout organs that can release hormones into the bloodstream. The term 'carcinoid' is an older name still widely used for the well-behaved, slow-growing end of the neuroendocrine tumor family. They arise most often in the lungs (bronchial carcinoids) and in the digestive tract — the small intestine, appendix, rectum, and stomach. Because they grow slowly, many are found early and incidentally, for example during an appendix operation, a colonoscopy, or a scan for another reason. A distinctive feature of some carcinoid tumors is that they can make hormones; when a tumor releases enough of these substances into the blood — usually once it has spread to the liver — it can cause 'carcinoid syndrome,' with flushing of the skin, diarrhea, wheezing, and over time heart-valve problems. Many carcinoids, however, cause no hormone symptoms at all. The behavior of these tumors is generally favorable: they tend to grow slowly and, when localized, are frequently cured by surgery alone. Even when they have spread, their slow pace means people can live well for many years with treatment. Care is highly specialized and involves a team, because the right plan depends on where the tumor started, its grade (how fast its cells divide), whether it makes hormones, and whether and where it has spread. Treatments range from surgery for localized tumors to hormone-blocking injections, liver-directed therapies, and a targeted form of radiation called peptide receptor radionuclide therapy (PRRT) for tumors that have spread.
The main types
Doctors group carcinoid tumors (well-differentiated neuroendocrine tumors) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Lung (bronchial) carcinoid | A neuroendocrine tumor of the airways; typical carcinoids are slow and often cured by surgery, while atypical carcinoids are somewhat more active and watched more closely. |
| Small-intestine (midgut) carcinoid | The classic carcinoid of the small bowel; often slow but can spread to the liver and is the most likely to cause carcinoid syndrome with flushing and diarrhea. |
| Appendiceal and rectal carcinoid | Frequently found incidentally during surgery or a scope; small ones are often cured by removal alone with an excellent outlook. |
| Gastric (stomach) carcinoid | Neuroendocrine tumors of the stomach lining, several subtypes of which behave differently; many small ones have a favorable course and are managed conservatively. |
Staging, in plain terms
Carcinoid tumors are staged using the TNM system — T for the size and extent of the main tumor, N for whether it has reached nearby lymph nodes, and M for spread to distant organs such as the liver. But for neuroendocrine tumors, stage tells only part of the story; grade is just as important. Grade measures how quickly the tumor's cells are dividing, judged by the mitotic count and a marker called Ki-67. Well-differentiated, low-grade tumors (the classic 'carcinoids') grow slowly and have a favorable outlook even when they have spread, whereas higher-grade tumors behave more aggressively. Where the tumor started also matters, because a small-intestine carcinoid, a lung carcinoid, and a rectal carcinoid each have their own behavior and treatment patterns. Doctors also assess whether the tumor makes hormones, since hormone-producing tumors require additional treatment to control symptoms. A special tool in neuroendocrine cancer is a scan called a DOTATATE PET, which lights up cells carrying somatostatin receptors; it not only shows where the tumor is but also predicts whether the tumor will respond to receptor-targeted treatments, including the targeted radiation therapy PRRT. Together, stage, grade, location, hormone activity, and receptor status guide whether a carcinoid is simply removed and watched, or treated with medicines and targeted radiation.
| TNM staging combined with tumor grade (how fast cells divide, by Ki-67 and mitotic count) | What it generally means |
|---|---|
| Localized | Tumor confined to where it started, with no spread to nodes or other organs; often cured by surgery alone, sometimes by a minor procedure for very small tumors. |
| Regional (lymph nodes) | Spread to nearby lymph nodes; usually treated with surgery to remove the tumor and involved nodes, with follow-up monitoring. |
| Metastatic (often to the liver) | Spread to distant organs, most commonly the liver; because these tumors grow slowly, this is treated as a long-term condition with hormone-blocking medicine, liver-directed therapy, and targeted radiation (PRRT). |
| Functioning tumor / carcinoid syndrome | Any stage where the tumor releases hormones causing flushing, diarrhea, or wheezing; hormone-blocking injections are added to control symptoms and protect the heart, alongside treatment of the tumor itself. |
The standard of care
Carcinoid Tumors (Well-Differentiated Neuroendocrine Tumors) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery
Removing the tumor is the main treatment for localized carcinoids and can be curative; even when the tumor has spread, surgery to reduce the bulk of disease can help control symptoms.
Somatostatin analog injections
Long-acting injections (octreotide or lanreotide) both control hormone symptoms and slow tumor growth — a cornerstone of treatment for tumors that have spread.
Peptide receptor radionuclide therapy (PRRT)
A targeted form of radiation given by infusion that homes in on neuroendocrine tumor cells throughout the body and irradiates them from within; effective for advanced tumors that carry somatostatin receptors.
Liver-directed therapies
For tumors that have spread to the liver, treatments delivered through the liver's blood supply — including bland, chemo, or radioactive bead embolization — can shrink tumors and ease symptoms.
Other systemic therapies
Targeted drugs (such as everolimus or sunitinib) and, for higher-grade tumors, chemotherapy are options to slow progression when needed.
How radiation treatment works
Radiation plays a distinctive and powerful role in carcinoid and other well-differentiated neuroendocrine tumors, and it works differently from the external-beam radiation used for many cancers. The signature treatment is peptide receptor radionuclide therapy, or PRRT. Most carcinoid tumors carry large numbers of a specific docking site on their surface called the somatostatin receptor. PRRT takes advantage of this: a small molecule that fits that receptor is joined to a radioactive atom (lutetium-177) and given as an intravenous infusion. The molecule circulates through the bloodstream and latches onto the tumor cells wherever they are in the body, and the attached radioactive atom then delivers its energy at very short range, damaging the DNA of the tumor cells from the inside while largely sparing surrounding healthy tissue. This is an example of a 'theranostic' approach — the very same receptor-targeting that is used to light the tumor up on a DOTATATE PET scan is used to deliver the treatment, so doctors can confirm in advance that a tumor is likely to respond. PRRT is especially valuable because carcinoids that have spread are often scattered in many places, where surgery and external-beam radiation cannot reach everything; an infused, tumor-seeking radiation can treat all those deposits at once. For liver metastases specifically, another internal radiation option delivers tiny radioactive beads through the liver's blood vessels, lodging them in the tumors. External-beam radiation, including precise stereotactic body radiation, still has a role for controlling specific problem areas — a painful bone deposit or a tumor pressing on something important. Because these tumors grow slowly, radiation is typically used to achieve durable, long-term control, often keeping advanced disease stable for years while preserving quality of life.
The main ways radiation is delivered for carcinoid tumors (well-differentiated neuroendocrine tumors):
Peptide receptor radionuclide therapy (PRRT)
A radioactive atom (lutetium-177) is attached to a molecule that locks onto somatostatin receptors on neuroendocrine tumor cells; given as an intravenous infusion, it travels through the body and delivers radiation directly to tumor cells wherever they are, sparing most normal tissue.
Theranostic pairing (scan then treat)
A DOTATATE PET scan first confirms that the tumor cells carry the receptors PRRT targets; the same targeting principle used to image the tumor is then used to treat it, so therapy is matched to tumors most likely to respond.
External-beam radiation for specific sites
Focused external-beam radiation, including stereotactic body radiation (SBRT), can control individual problem spots — such as a painful bone metastasis or a tumor pressing on a structure — even though it is not the main treatment for widespread disease.
Selective internal radiation (radioembolization)
For liver metastases, tiny radioactive beads delivered through the liver's blood vessels lodge in the tumors and irradiate them from within while sparing much of the healthy liver.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
PRRT improves outcomes in advanced neuroendocrine tumors: Randomized trials established that lutetium-177 PRRT significantly improves progression-free survival compared with standard hormone therapy alone in advanced, receptor-positive neuroendocrine tumors, and newer studies support using it earlier in the treatment course.[1]
NETTER-1 and subsequent PRRT trials
Somatostatin analogs slow tumor growth, not just symptoms: Long-acting octreotide and lanreotide were shown to slow the growth of well-differentiated neuroendocrine tumors, in addition to controlling hormone-related symptoms, making them a foundational therapy for advanced disease.[2]
PROMID and CLARINET trials
DOTATATE PET improves detection and treatment selection: Somatostatin-receptor PET imaging detects neuroendocrine tumors more accurately than older scans and identifies which patients are candidates for receptor-targeted radiation therapy, improving both staging and treatment planning.[3]
Somatostatin-receptor PET imaging studies
Common questions
Is a carcinoid tumor cancer? Yes, but usually a slow-growing kind. Carcinoid tumors are well-differentiated neuroendocrine tumors, which tend to grow much more slowly than most cancers. Many localized ones are cured by surgery, and even when they spread, their slow pace means people often live well for many years with treatment. A smaller number behave more aggressively, which is why grade — how fast the cells divide — is assessed alongside stage.
What is PRRT, and how is it different from regular radiation? PRRT (peptide receptor radionuclide therapy) is a targeted radiation given as an infusion rather than aimed from a machine. A tumor-seeking molecule carries a radioactive atom through the bloodstream and attaches to neuroendocrine tumor cells wherever they are, delivering radiation from the inside. This lets it treat tumors scattered in many places at once — something external-beam radiation, which targets one area, cannot do.
What is carcinoid syndrome? Carcinoid syndrome happens when a tumor releases hormone-like substances into the blood, usually after it has spread to the liver. It causes flushing of the skin, diarrhea, and sometimes wheezing, and over time can affect the heart valves. Long-acting somatostatin-analog injections control these symptoms well and also help slow the tumor, which is why they are a cornerstone of treatment for hormone-producing tumors.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.